Bullish Moving Averages
14
Bearish Moving Averages
2
Back Stocks profile
Stock analysis tool for investors
Performance
Today’s low
12.80Today’s High
14.1052W low
8.1052W High
19.70Open Price
13.60Prev. Close
13.2500Volume
65599.00Value
919041.99Fundamentals
Market Cap
63.90
Price to Earnings
-14.20
Price to Book Value
1.60
Dividend Yield
0.00
PE to Growth
-0.70
Op Revenue TTM
10.29
Net Profit TTM
-4.51
Cash From Operating Activity
-4.92
Return on Equity %
-11.15
EMA & SMA
DELIVERY AND VOLUME
DAILY AVG. DELIVERY VOLUME %
05 Jul, 2024
100
Week
100
Month
100
LEGEND
Positive Indicator
Neutral Indicator
Negative Indicator
RESISTANCE AND SUPPORT
13.64
PIVOT
First Resistance
14.45
Second Resistance
14.90
Third Resistance
15.71
First Support
13.19
Second Support
12.38
Third Support
11.93
Relative Strength Index
60.21
Money Flow Index
43.53
MACD
-0.03
MACD Signal
-0.13
Average True Range
0.9
Average Directional Index
13.16
Rate of Change (21)
6.14
Rate of Change (125)
-14.36
Commodity Channel Index
87.1
Williams %R
-7.7
BETA
1 Month
0.22
3 Month
0.3
1 Year
0.39
3 Year
0.33
PRICE CHANGE ANALYSIS
↑ 10.75%
1 Week
Low
High
12.12
14.08
↑ 5.74%
1 Month
Low
High
11.85
14.2
↑ 3.24%
3 Months
Low
High
11.85
15.15
↓ -18.5%
6 Months
Low
High
10.43
17.55
↑ 38.44%
1 Year
Low
High
8.12
19.7
| Indicator | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Graph |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Qtr Revenue cr | 3.23 | 1.73 | 3.55 | 2.11 | 1.29 | 0.00 | 0.00 | 0.00 | 0.30 | 0.05 | 0.24 | |
| Operating Expenses Qtr | 2.87 | 3.45 | 4.64 | 2.90 | 2.38 | 0.33 | 0.15 | 0.20 | 0.31 | 0.27 | 0.59 | |
| Operating Profit Qtr | 0.26 | -1.74 | -1.17 | -0.92 | -1.38 | -0.33 | -0.15 | -0.20 | -0.31 | -0.16 | -0.30 | |
| EBIDT Qtr Cr | 0.36 | -1.72 | -1.09 | -0.79 | -1.09 | -0.33 | -0.15 | -0.20 | -0.01 | -0.22 | -0.35 | |
| Depreciation Qtr | 0.18 | 0.18 | 0.18 | 0.17 | 1.11 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | |
| Net Profit Qtr | 0.09 | -1.63 | -2.02 | -0.95 | -3.87 | -0.96 | -0.24 | -0.59 | 2.11 | -0.63 | -2.19 | |
| Basic EPS Qtr | 0.02 | -0.33 | -0.46 | -0.23 | -1.05 | -0.27 | -0.08 | -0.18 | 0.56 | -0.17 | -0.60 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total Revenue Annual | 10.62 | 1.40 | 0.56 | 1.58 | 26.51 | |
| Operating Expenses Annual Cr | 13.86 | 5.45 | 1.61 | 3.00 | 27.56 | |
| Operating Profit Annual | -3.57 | -4.44 | -1.21 | -1.73 | -4.80 | |
| Operating Profit Margin Annual % | -33.62 | -316.77 | -216.06 | -109.14 | -18.10 | |
| Total Expenses Annual Cr | 15.80 | 7.28 | 3.12 | 5.27 | 30.44 | |
| EBIDT Annual Cr | -3.24 | -4.05 | -1.04 | -1.41 | -1.05 | |
| EBIDT Annual margin % | -30.49 | -288.30 | -186.49 | -89.04 | -3.96 | |
| Depreciation | 0.72 | 0.62 | 0.62 | 0.73 | 1.35 | |
| PAT Before ExtraOrdinary Items Annual Cr | -4.51 | -5.66 | -0.83 | -1.89 | -3.68 | |
| Net Profit Annual | -4.51 | -5.66 | -0.83 | -1.89 | -3.68 | |
| Basic EPS Annual | -1.03 | -1.54 | -0.24 | -0.54 | -1.22 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total ShareHolders Funds Annual | 40.46 | 36.71 | 35.45 | 32.85 | 29.64 | |
| Minority Interest Liability Annual Cr | - | - | - | - | - | |
| Total Non Current Liabilities Annual Cr | 3.02 | 5.24 | 9.44 | 8.76 | 5.56 | |
| Total Current Liabilities Annual Cr | 14.49 | 14.08 | 10.70 | 9.25 | 15.92 | |
| Total Capital Plus Liabilities Annual Cr | 57.98 | 56.03 | 55.59 | 50.85 | 51.12 | |
| Fixed Assets Annual | 29.14 | 29.07 | 28.41 | 29.01 | 29.44 | |
| Total Non Current Assets Annual | 34.58 | 32.28 | 40.24 | 35.62 | 29.94 | |
| Total Current Assets Annual | 23.40 | 23.75 | 15.35 | 15.24 | 21.19 | |
| Total Assets Annual | 57.98 | 56.03 | 55.59 | 50.85 | 51.12 | |
| Contingent Liabilities plus Commitments Annual Cr | - | 0.00 | 0.00 | 0.00 | 0.00 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Cash from Operating Activity Annual | -4.92 | -1.71 | -0.99 | -6.75 | 0.80 | |
| Cash from Investing Activity Annual | -0.79 | -1.27 | -0.01 | -0.30 | -1.73 | |
| Cash from Financing Annual Activity | 5.59 | 3.11 | 0.94 | 6.96 | 0.28 | |
| Net Cash Flow Annual | - | 0.13 | -0.07 | -0.09 | -0.64 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Book Value Per Share Annual | 8.58 | 9.77 | 9.64 | 8.93 | 9.76 | |
| ROE Annual % | -11.15 | -15.42 | -2.34 | -5.73 | -12.40 | |
| ROCE Annual % | -9.10 | -11.11 | -3.70 | -5.14 | -6.80 | |
| Total Debt to Total Equity Annual | 0.20 | 0.27 | 0.35 | 0.46 | 0.52 | |
| EBDIT Annual Margin % | -31.47 | -403.02 | -264.79 | -111.43 | -4.61 |
| Indicator | Graph |
|---|---|
| Total Qtr Revenue cr | |
| Operating Expenses Qtr | |
| Operating Profit Qtr | |
| EBIDT Qtr Cr | |
| Depreciation Qtr | |
| Net Profit Qtr | |
| Basic EPS Qtr |
| Indicator | Graph |
|---|---|
| Total Revenue Annual | |
| Operating Expenses Annual Cr | |
| Operating Profit Annual | |
| Operating Profit Margin Annual % | |
| Total Expenses Annual Cr | |
| EBIDT Annual Cr | |
| EBIDT Annual margin % | |
| Depreciation | |
| PAT Before ExtraOrdinary Items Annual Cr | |
| Net Profit Annual | |
| Basic EPS Annual |
| Indicator | Graph |
|---|---|
| Total ShareHolders Funds Annual | |
| Minority Interest Liability Annual Cr | |
| Total Non Current Liabilities Annual Cr | |
| Total Current Liabilities Annual Cr | |
| Total Capital Plus Liabilities Annual Cr | |
| Fixed Assets Annual | |
| Total Non Current Assets Annual | |
| Total Current Assets Annual | |
| Total Assets Annual | |
| Contingent Liabilities plus Commitments Annual Cr |
| Indicator | Graph |
|---|---|
| Cash from Operating Activity Annual | |
| Cash from Investing Activity Annual | |
| Cash from Financing Annual Activity | |
| Net Cash Flow Annual |
| Indicator | Graph |
|---|---|
| Book Value Per Share Annual | |
| ROE Annual % | |
| ROCE Annual % | |
| Total Debt to Total Equity Annual | |
| EBDIT Annual Margin % |
| Name | Holding Percent | Holding Id | Pledged % | Locked % |
|---|
| Name | Holding Percent | Holding Id | Pledged % | Locked % |
|---|---|---|---|---|
| ANDHRA PRADESH INDUSTRIAL DEVELOPMENT CORPORATION LIMITED | 1.6 | 80278506 | 0 | 0 |
| VISTA PHARMACEUTICALS INC | 14.03 | 80278504 | 0 | 0 |
| DHANANJAYA ALLI | 6.16 | 80278508 | 0 | 0 |
| VASANT V ALLI | 3.41 | 80278509 | 0 | 0 |
| PADMAVATHI ALLI | 0.99 | 80278510 | 0 | 0 |
| VAMSI V ALLI | 0.89 | 80278511 | 0 | 0 |
| ROSHNI ALLI | 0.73 | 80278512 | 0 | 0 |
| Name | Holding Percent | Holding Id |
|---|
| Name | Holding Percent | Holding Id |
|---|---|---|
| SURESH GADALAY | 6.06 | 80278520 |
| KAMAL GADALAY | 3.82 | 80278521 |
| Deepthi Pachipala | 2.56 | 80278522 |
| KESHAVA MURTHY SHIVA SHANKAR | 2.68 | 80278524 |
| RAJENDAR BALAKRISHNA | 1.49 | 80278525 |
| UMAKANTH KATTA | 11.51 | 80278527 |
| Pavan sathvik Gilaka | 9.64 | 80278528 |
| Murali Meraga | 8.49 | 80278529 |
| Ex-Date | Dividend Amount | Dividend Type | Record Date | Instrument Type |
|---|
| Ex-Date | Split Ratio | Record Date |
|---|
| Ex-Date | Purpose | Notes |
|---|---|---|
| May 28, 2024 | Audited Results | - |
| Feb 10, 2024 | Quarterly Results | - |
| Nov 10, 2023 | Quarterly Results | - |
| Aug 12, 2023 | Quarterly Results | - |
| May 30, 2023 | Audited Results | - |
| Feb 13, 2023 | Quarterly Results | - |
| Nov 14, 2022 | Quarterly Results | - |
| Aug 13, 2022 | Quarterly Results | - |
| May 30, 2022 | Quarterly Results | - |
| Feb 14, 2022 | Quarterly Results | - |
| Nov 13, 2021 | Quarterly Results | - |
| Aug 14, 2021 | Quarterly Results & A.G.M. | - |
| Jun 30, 2021 | Audited Results | - |
| Feb 12, 2021 | Quarterly Results | - |
| Nov 12, 2020 | Quarterly Results | - |
| Sep 14, 2020 | Quarterly Results | - |
| Jul 29, 2020 | Audited & Quarterly Results | (Revised) |
| Jul 20, 2020 | Audited Results & Others | Inter alia, To appoint Secretarial Auditor for the financial year 2019-2020 and Internal Auditors for the financial year 2020-21 of the Company. |
| Jun 30, 2020 | Audited Results | - |
| May 25, 2020 | Preferential Issue of shares | Inter-alia, 1. Proposal to raise funds by way of issue of equity shares on preferential basis. |
| Feb 13, 2020 | Quarterly Results | - |
| Nov 07, 2019 | Quarterly Results | - |
| Aug 14, 2019 | Quarterly Results | - |
| May 30, 2019 | Audited Results | - |
| Feb 06, 2019 | Quarterly Results | - |
| Nov 14, 2018 | Quarterly Results | - |
| Aug 13, 2018 | Quarterly Results | - |
| Jun 29, 2018 | Others | To consider and approve the Board of Directors' Report on the company's activities for the financial year ended March 31st, 2018. |
| May 30, 2018 | Audited Results | - |
| May 10, 2018 | Others | - |
| Mar 22, 2018 | Others | 1. Appointment of Mr. Chittajallu Anand (DIN: 05280486), as Additional Director (Non- Executive, Independent) on the Board of the Company. |
| Feb 24, 2018 | Others | Approve appointment of Additional Director (Non-Executive Independent). |
| Feb 10, 2018 | Quarterly Results | - |
| Feb 07, 2018 | To consider Preferential issue | - |
| Jan 09, 2018 | Others | - |
| Dec 07, 2017 | Others | Inter alia, considered and approved the following :1) Allotment of balance 7,00,000 convertible warrants to the others. |
| Nov 29, 2017 | Others | Allotment of Convertible Warrants to the promoters and the others, subject to the in-principle approval from BSE for allotment of Warrants. |
| Nov 20, 2017 | Quarterly Results | - |
| Sep 30, 2017 | Others | - |
| Aug 18, 2017 | Quarterly Results | (Revised) |
| Jul 21, 2017 | Others | - |
| Jul 07, 2017 | Others | - |
| May 30, 2017 | Audited Results | - |
| May 15, 2017 | Others | 1.Acceptance of Resignation of Company Secretary and Key Managerial Personnel Ms. Lakshmi Adduri. 2.Approval of appointment of Mr. Arjun Upadhyay as Company Secretary. |
| Apr 13, 2017 | Others | 1.Allotment of balance equity shares and convertible warrants to the promoters. 2.Any other business with the permission of the Chair. |
| Mar 31, 2017 | Others | 1. Allotment of equity shares and convertible warrants to the promoters, subject to the shareholders' approval in the ensuing EGM scheduled to be held on 30.03.2017. |
| Mar 07, 2017 | Others | Issue of 18,00,000 equity shares and 44,50,000 convertible warrants to the promoters on preferential basis at an issue price of Rs. 24.05/- per equity share/warrant. |
| Feb 13, 2017 | Quarterly Results | - |
| Nov 11, 2016 | Quarterly Results | - |
| Oct 24, 2016 | Others | 1. To fill the casual vacancy of Statutory Auditors of the Company for the FY 2016-17. 2. Appointment of Internal Auditors. |
| Aug 12, 2016 | Quarterly Results | - |
| May 27, 2016 | Audited Results | - |
| Feb 09, 2016 | Quarterly Results | To considered and approved appointment of Mr. Manoj Kumar Koyalkar, Practicing Company Secretary as Secretarial Auditor for the financial year 15-16. |
| Nov 12, 2015 | Quarterly Results | - |
| Aug 10, 2015 | Quarterly Results | - |
| Jul 02, 2015 | Others | To consider Split and issue of New Share Certificates pursuant to the Scheme of Reduction of Share Capital of the Company, |
| May 28, 2015 | Audited Results | - |
| Apr 20, 2015 | Appointment of CFO & Secretary | Appointment of Mr. Suneel Pachipala as Chief Financial Officer (CFO) of the Company. |
| Feb 11, 2015 | Quarterly Results | - |
| Nov 14, 2014 | Quarterly Results | - |
| Aug 01, 2014 | Quarterly Results | - |
| May 29, 2014 | Audited Results | - |
| Feb 12, 2014 | Quarterly Results | - |
| Nov 14, 2013 | Quarterly Results | - |
| Aug 14, 2013 | Quarterly Results & Audited Results | - |
| May 14, 2013 | Quarterly Results | - |
| Feb 12, 2013 | Quarterly Results | - |
| Aug 14, 2012 | Quarterly Results | - |
| May 11, 2012 | Quarterly Results | - |
| Feb 10, 2012 | Quarterly Results | - |
| Nov 09, 2011 | Quarterly Results | - |
| Aug 10, 2011 | Quarterly Results | - |
| May 02, 2011 | Audited Results | - |
| Jan 31, 2011 | Quarterly Results | - |
| Oct 30, 2010 | Quarterly Results | - |
| Jul 30, 2010 | Quarterly Results | - |
| Apr 30, 2010 | Quarterly Results | - |
| Jan 29, 2010 | Quarterly Results | - |
| Oct 30, 2009 | Quarterly Results | - |
| Aug 25, 2009 | Audited Results | - |
| Jul 31, 2009 | Quarterly Results | - |
| Apr 30, 2009 | Quarterly Results | - |
| Jan 31, 2009 | Quarterly Results | - |
| Dec 15, 2008 | Allotment of equity shares | To allot 42,71,395 Shares of Rs 10/- each at a premium of Rs 3.60 subsequent to exercise of option by the warrant holders. |
| Nov 15, 2008 | To convene AGM & Others | For the purpose of approval of Directors Report & Notice convening the AGM. |
| Oct 31, 2008 | Quarterly Results | - |
| Jul 28, 2008 | To consider allotment of Warrants | To allot 43,08,000 warrants of Rs 10/- each at a price of Rs 13.60 to promoter and others on preferential basis. |
| Jan 31, 2008 | Quarterly Results | - |
| Jan 28, 2008 | To consider issue of equity shares | inter alia, to consider, the proposal of issue of Equity Shares / Warrants to the Promoters and others. |
| Oct 31, 2007 | Quarterly Results | - |
| Aug 27, 2007 | Audited Results | - |
| Jul 31, 2007 | Quarterly Results | - |
| Jun 06, 2007 | Increase in Authorised Capital | - |
| Apr 30, 2007 | Quarterly Results | - |
| Jan 31, 2007 | Quarterly Results | - |
| Oct 31, 2006 | Quarterly Results | - |
| Oct 04, 2006 | Accounts | - |
| Jul 29, 2006 | Quarterly Results | - |
| Apr 28, 2006 | Quarterly Results | - |
| Jan 31, 2006 | Quarterly Results | - |
| Jan 24, 2006 | Allotment of equity shares | - |
| Dec 22, 2005 | Approval of business plan | Approval of business plan for Commercial production of ANDA (USFDA) product (SULFAMETHOXAZOLE + TRIMETHOPRIM) & Approval of business plan for products tie up with World Foundation Organization. |
| Dec 12, 2005 | Increase in Authorised Capital | From 11 crores to Rs.11.50 crores |
| Oct 28, 2005 | Quarterly Results | - |
| Jul 30, 2005 | Quarterly Results | - |
| Jul 09, 2005 | Preferential Issue of shares | - |
| Apr 29, 2005 | Quarterly Results | - |
| Feb 19, 2005 | Others | Have allotted 184044 equity shares to Vista Pharmaseceuticals Inc. |
| Jan 31, 2005 | Quarterly Results | - |
| Nov 29, 2004 | Others | Allotted 3,71,481 fully convertible warrants on preferential basis to Vista Pharmaceuticals Inc. which was earlier approved in the AGM held on 30-09-2004. |
| Jul 31, 2004 | Quarterly Results | - |
| Apr 30, 2004 | Quarterly Results | - |
| Dec 26, 2003 | Preferential Issue of shares | allotted 352907 fully convertile warrants to Vista Pharmaceuticals Inc. |
| Oct 30, 2003 | Quarterly Results | - |
| Jul 31, 2003 | Quarterly Results | - |
| Apr 29, 2003 | Quarterly Results | - |
| Jan 30, 2003 | Quarterly Results | - |
| Oct 30, 2002 | Quarterly Results | - |
| Apr 29, 2002 | Quarterly Results | - |
| Jan 30, 2002 | Quarterly Results | - |
| Oct 30, 2001 | Quarterly Results | - |
| Jul 27, 2001 | Quarterly Results | - |
| Apr 27, 2001 | Quarterly Results | - |
| Jan 31, 2001 | Quarterly Results | - |
| Oct 31, 2000 | Quarterly Results | - |
| Jul 28, 2000 | Quarterly Results | - |
| Apr 28, 2000 | Quarterly Results | - |
| Jan 31, 2000 | Quarterly Results | - |
| Oct 30, 1999 | Quarterly Results | - |
| Jul 29, 1999 | Quarterly Results | - |
| Apr 28, 1999 | Quarterly Results | - |
| Jan 28, 1999 | Quarterly Results | - |
| Oct 31, 1998 | Quarterly Results | - |
| Aug 22, 1998 | Pvt. Placements | - |
| Jul 13, 1998 | Half Yearly Results | - |
| May 20, 1998 | Half Yearly Results | - |
| Nov 24, 1997 | Half Yearly Results | - |
| Ex-Date | Bonus Ratio | Record Date |
|---|
28 Jun 2024
VISTA PHARMACEUTICALS LTD. - 524711 - Closure of Trading Window
Closure of Trading window for the quarter ended 30.06.2024
14 Jun 2024
VISTA PHARMACEUTICALS LTD. - 524711 - Announcement under Regulation 30 (LODR)-Allotment
Circular Resolution
21 May 2024
VISTA PHARMACEUTICALS LTD. - 524711 - Board Meeting Intimation for Approval Of Audited Financial Results For The Quarter And Year Ended 31.03.2024.
VISTA PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2024 ,inter alia, to consider and approve 1. Audited financial results for the quarter and year ended 31.03.2024. 2. Audit Report for quarter and year ended 31.03.2024. 3. Conversion of warrants into equity shares of the Company to the Non-Promoters, subject to the depositing the balance outstanding amount for conversion of warrants into the equity shares of the Company. 4. Any other business with the permission of the Chair.
30 Apr 2024
VISTA PHARMACEUTICALS LTD. - 524711 - Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
Format of the Annual Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1 Name of Company VISTA PHARMACEUTICALS LTD. 2 CIN NO. L24239TG1991PLC012264 3 Report filed for FY 2023-2024 Details of the Current block (all figures in Rs crore): 4 2 - year block period (Specify financial years)* FY 2023-24, 2024-25 5 Incremental borrowing done in FY (T)(a) 0.00 6 Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a) 0.00 7 Actual borrowing done through debt securities in FY (T)(c) 0.00 8 Shortfall in the borrowing through debt securities, if any, for FY (T - 1) carried forward to FY (T) (d) 0 8Quantum of (d), which has been met from (c)(e)* 0 9 Shortfall, if any, in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative, write 'nil'}* 0 Details of penalty to be paid, if any, in respect to previous block (all figures in Rs crore): 2 - year Block period (Specify financial years)FY 2023-24 , 2022-23 Amount of fine to be paid for the block, if applicable Fine = 0.2% of {(d) - (e)}#0.00 Name of the Company Secretary :-Barkha JainDesignation :-Company Secretary Name of the Chief Financial Officer :- Suneel Pachipala Designation : -Chief Financial Officer Date: 30/04/2024
30 Apr 2024
VISTA PHARMACEUTICALS LTD. - 524711 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyVISTA PHARMACEUTICALS LTD. 2CIN NO.L24239TG1991PLC012264 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY 0 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Bharka Jain Designation: Company Secretary EmailId: [email protected] Name of the Chief Financial Officer: suneel Pachipala Designation: Chief Financial Officer EmailId: [email protected] Date: 30/04/2024 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
21 Apr 2024
VISTA PHARMACEUTICALS LTD. - 524711 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under reg 74 (5) of SEBI (DP) Regulations, 2018
29 Mar 2024
VISTA PHARMACEUTICALS LTD. - 524711 - Closure of Trading Window
Closure of Trading Window
